New Partnership Agreement & Licensed Clinical Team Established with Three Senior Hires
Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, announces it has established a management services organization agreement with Connected Health Medicine PC (“Connected Health”), a state licensed Professional Corporation that will …
Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model
Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™ early-stage risk assessment testing and care management …
First Demonstration Contract with Mount Sinai Employee Health Plan for Resilience-Based Digital Chronic Condition Management
Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, is pleased to announce that it has signed an agreement to provide an Inflammatory Bowel Disease (“IBD”) demonstration programme for the Mount Sinai …
Breaking Boundaries: How Yasmin Hurd, PhD, is Paving New Ground for Addiction Treatment
Neuroscientist Yasmin Hurd, PhD, has a natural way of connecting with people. Whether through her many research publications, a TED Talk, or during a virtual meeting with two team members of Mount Sinai Innovation Partners (MSIP), it is easy to be inspired …
Mount Sinai Health System Launches Elementa Labs, A Virtual Incubator Program
Elementa Labs will connect health care startup companies with Mount Sinai’s vast network of research and clinical experts to advance groundbreaking health care innovations. Mount Sinai Innovation Partners (MSIP), the commercialization engine of the Mount Sinai Health System (Mount Sinai) in New …
Kantaro’s Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order
-COVID-SeroKlir detects both the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity -Available immediately and can be used in Canadian laboratories without proprietary equipment Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health …
UK Vivan Therapeutics Secures Expanded Drug Discovery & Development Platform From Mount Sinai Health System in New York
My Personal Therapeutics Ltd. (trading as Vivan Therapeutics), a UK-based company, announces an expansion of its licensed technology rights from Mount Sinai Health System. Scientists at the Icahn School of Medicine at Mount Sinai Center for Personalized Cancer Therapeutics (CPCT) in New …
Meet Charles Mobbs, PhD, of Team Gilga-Med: the Winner of the Mount Sinai Pitch Challenge 2021
Charles Mobbs, PhD, Professor in the Departments of Geriatrics and Palliative Care, Neuroscience, and Medicine at the Icahn School of Medicine at Mount Sinai, won the Mount Sinai Pitch Challenge on May 5 by presenting the healthcare startup Gilga-Med. Read the Q&A …
Kantaro’s COVID-SeroKlir Antibody Test Named as a Finalist for Fast Company’s 2021 World Changing Ideas Awards
Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 …